Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma

Authors:
  • ESEric P. Suan
    Eric P. Suan
  • RSRaymond N. Sjaarda
    Raymond N. Sjaarda
  • DCDavid G. Callanan
    David G. Callanan
  • JDJoseph DeFaller
    Joseph DeFaller

Abstract
Intravitreal administration of triamcinolone acetonide has become routine in the treatment of numerous vascular conditions of the posterior segment including neovascular age-related macular degeneration and macular edema from a variety of causes.1 Corticosteroid-related ocular hypertension is a well-recognized complication of intravitreal triamcinolone acetonide therapy. In studies of intravitreal triamcinolone for various disease states, the incidence of elevated intraocular pressure (IOP) of more than 21 mm Hg was approximately 40% within 9 to 10 months of injection.2,3